Valeric acid

As a physiologically active substance of short-chain fatty acids, valeric acid exerts its effects by regulating the balance of intestinal microecology and inhibiting the release of pro-inflammatory factors. Clinically, it is mainly used for the adjuvant treatment of mild to moderate diarrhea and inflammatory bowel disease related to intestinal flora disorder, and can also be used as a pharmaceutical excipient in the preparation of pH regulators for topical creams and sustained and controlled release preparations. The applicable population includes patients with intestinal dysfunction caused by improper diet, people receiving long-term conditioning for chronic enteritis, and industrial users for the production of special preparations.

At present, the global market size of valeric acid API is approximately USD 230 million, with a compound annual growth rate of 6.8% in the past three years. The growth momentum mainly comes from the expansion of the intestinal microecological preparation track and the popularization of sustained and controlled release preparation processes. The competitive landscape is characterized by concentrated production capacity. Chinese and European enterprises together account for more than 85% of the global supply share, among which domestic production capacity accounts for more than 60%, making China a major global exporter by virtue of cost advantages. The procurement demand for valeric acid from domestic intestinal preparations related to centralized procurement is increasing year by year, the overall market price system is stable, and the capacity utilization rate of leading enterprises has remained above 90% throughout the year.

There is no exclusive original research drug for valeric acid for the time being. As a basic pharmaceutical raw material and pharmaceutical excipient, its medicinal grade standard is included in the pharmacopoeia systems of many countries. At present, 12 domestic enterprises have obtained CDE API registration numbers for medicinal grade valeric acid, among which 8 are in Class A status and can be directly associated with the marketing of preparations. There are 37 domestic approved preparations containing valeric acid, covering multiple dosage forms such as oral solutions, topical creams, sustained and controlled release tablets, etc. A total of 21 valeric acid API dossiers are included in the US FDA DMF database, among which more than 70% are in valid status. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for valeric acid, most of which are available in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. The products comply with the regulatory requirements of the Chinese Pharmacopoeia and FDA, and can meet the reference standard use needs of the whole process of API R&D, quality research, and declaration and registration.